BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 28889723)

  • 1. Expression of C-myc and β-catenin and their correlation in triple negative breast cancer.
    Wang J; Li M; Chen D; Nie J; Xi Y; Yang X; Chen Y; Yang Z
    Minerva Med; 2017 Dec; 108(6):513-517. PubMed ID: 28889723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A subgroup of microRNAs defines PTEN-deficient, triple-negative breast cancer patients with poorest prognosis and alterations in RB1, MYC, and Wnt signaling.
    Wang DY; Gendoo DMA; Ben-David Y; Woodgett JR; Zacksenhaus E
    Breast Cancer Res; 2019 Jan; 21(1):18. PubMed ID: 30704524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression and significance of Wnt signaling components and their target genes in breast carcinoma.
    He Y; Liu Z; Qiao C; Xu M; Yu J; Li G
    Mol Med Rep; 2014 Jan; 9(1):137-43. PubMed ID: 24190141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CircRNA_069718 promotes cell proliferation and invasion in triple-negative breast cancer by activating Wnt/β-catenin pathway.
    Zhang J; Xu HD; Xing XJ; Liang ZT; Xia ZH; Zhao Y
    Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5315-5322. PubMed ID: 31298383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nek2B activates the wnt pathway and promotes triple-negative breast cancer chemothezrapy-resistance by stabilizing β-catenin.
    Shen H; Yan W; Yuan J; Wang Z; Wang C
    J Exp Clin Cancer Res; 2019 Jun; 38(1):243. PubMed ID: 31174562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of postoperative survival of triple-negative breast cancer based on nomogram model combined with expression of HIF-1α and c-myc.
    Cui J; Jiang H
    Medicine (Baltimore); 2019 Oct; 98(40):e17370. PubMed ID: 31577739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined expression of aldehyde dehydrogenase 1A1 and β-catenin is associated with lymph node metastasis and poor survival in breast cancer patients following cyclophosphamide treatment.
    Sun M; Zhao H; Xiao Q; Yu Z; Song Z; Yao W; Tang H; Guan S; Jin F; Wei M
    Oncol Rep; 2015 Dec; 34(6):3163-73. PubMed ID: 26398662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulator of G protein signaling 20 correlates with clinicopathological features and prognosis in triple-negative breast cancer.
    Li Q; Jin W; Cai Y; Yang F; Chen E; Ye D; Wang Q; Guan X
    Biochem Biophys Res Commun; 2017 Apr; 485(3):693-697. PubMed ID: 28237701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. β-catenin regulates c-Myc and CDKN1A expression in breast cancer cells.
    Xu J; Chen Y; Huo D; Khramtsov A; Khramtsova G; Zhang C; Goss KH; Olopade OI
    Mol Carcinog; 2016 May; 55(5):431-9. PubMed ID: 25663530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma.
    Bland KI; Konstadoulakis MM; Vezeridis MP; Wanebo HJ
    Ann Surg; 1995 Jun; 221(6):706-18; discussion 718-20. PubMed ID: 7794075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HAGE in Triple-Negative Breast Cancer Is a Novel Prognostic, Predictive, and Actionable Biomarker: A Transcriptomic and Protein Expression Analysis.
    Abdel-Fatah TM; McArdle SE; Agarwal D; Moseley PM; Green AR; Ball GR; Pockley AG; Ellis IO; Rees RC; Chan SY
    Clin Cancer Res; 2016 Feb; 22(4):905-14. PubMed ID: 26240276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-myc protein expression in human breast carcinoma: prognostic implications.
    Mizukami Y; Nonomura A; Takizawa T; Noguchi M; Michigishi T; Nakamura S; Ishizaki T
    Anticancer Res; 1995; 15(6B):2899-905. PubMed ID: 8669886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation of molecular alterations of AKT-3 in triple-negative breast cancer.
    O'Hurley G; Daly E; O'Grady A; Cummins R; Quinn C; Flanagan L; Pierce A; Fan Y; Lynn MA; Rafferty M; Fitzgerald D; Pontén F; Duffy MJ; Jirström K; Kay EW; Gallagher WM
    Histopathology; 2014 Apr; 64(5):660-70. PubMed ID: 24138071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Favorable prognosis in colorectal cancer patients with co-expression of c-MYC and ß-catenin.
    Lee KS; Kwak Y; Nam KH; Kim DW; Kang SB; Choe G; Kim WH; Lee HS
    BMC Cancer; 2016 Sep; 16(1):730. PubMed ID: 27619912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beta-catenin up-regulates the expression of cyclinD1, c-myc and MMP-7 in human pancreatic cancer: relationships with carcinogenesis and metastasis.
    Li YJ; Wei ZM; Meng YX; Ji XR
    World J Gastroenterol; 2005 Apr; 11(14):2117-23. PubMed ID: 15810077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of cMET aberration by immunohistochemistry and fluorescence in situ hybridization (FISH) in triple negative breast cancers.
    Wang M; Liang L; Lei X; Multani A; Meric-Bernstam F; Tripathy D; Wu Y; Chen H; Zhang H
    Ann Diagn Pathol; 2018 Aug; 35():69-76. PubMed ID: 29843069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. c-Met and ERβ expression differences in basal-like and non-basal-like triple-negative breast cancer.
    Ren X; Yuan L; Shen S; Wu H; Lu J; Liang Z
    Tumour Biol; 2016 Aug; 37(8):11385-95. PubMed ID: 26968553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RBMS3 is a tumor suppressor gene that acts as a favorable prognostic marker in lung squamous cell carcinoma.
    Liang YN; Liu Y; Meng Q; Li X; Wang F; Yao G; Wang L; Fu S; Tong D
    Med Oncol; 2015 Feb; 32(2):459. PubMed ID: 25588924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High Myc expression and transcription activity underlies intra-tumoral heterogeneity in triple-negative breast cancer.
    Gupta N; Jung K; Wu C; Alshareef A; Alqahtani H; Damaraju S; Mackey JR; Ghosh S; Sabri S; Abdulkarim BS; Bigras G; Lai R
    Oncotarget; 2017 Apr; 8(17):28101-28115. PubMed ID: 28427212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of NY-ESO-1 in Triple-Negative Breast Cancer Is Associated with Tumor-Infiltrating Lymphocytes and a Good Prognosis.
    Lee HJ; Kim JY; Song IH; Park IA; Yu JH; Gong G
    Oncology; 2015; 89(6):337-44. PubMed ID: 26413775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.